new version V2017

Empagliflozin antidiabetic drugs
Description Results

Jardiance - BI-10773 - BI10773 - BI 10773      

  • Group by...

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetes type 2

EMPA-REG OUTCOMEempagliflozinplacebo - NCT01131676
Kadowaki, 2013empagliflozin -
Ferrannini, 2013empagliflozinplacebo - NCT00789035
EMPA-REG MONO (Roden) vs placebo, 2013empagliflozinplacebo - NCT01177813
EMPA-REG PIO (Kovacs), 2013empagliflozinplacebo (add on MET+/-PIO) - NCT01210001
Rosenstock DOUBLON ???, 2013empagliflozinplacebo (add-on INS) -
Rosenstock, 2013empagliflozinplacebo (add-on MET) - NCT00749190
Kadowaki , 2014empagliflozin -
Ridderstrale, 2014empagliflozinGlimepiride + MET - NCT01167881
Barnett, 2014empagliflozinplacebo - NCT01164501
Rosenstock (1245.49), 2014empagliflozinplacebo (add-on INS+/-MET) - NCT01306214
EMPA-REG MET (Haring), 2014empagliflozinplacebo (add-on MET) - NCT01159600
DeFronzo, 2015empagliflozinlinagliptin (add-on MET) - NCT01422876
Lewin, 2015empagliflozinlinagliptin (monotherapy) - NCT01422876
EMPA-REG OUTCOME, 2015empagliflozinplacebo Low risk of bias ConclusiveNCT01131676
Kadowaki, 2015empagliflozinplacebo - NCT01193218
Ross, 2015empagliflozinplacebo (add-on MET) - e2012-000905-53
Araki, 2015empagliflozinplacebo (add-on standard treatment) - NCT01368081
1275.9 ongoing empagliflozinadd-on linagliptin + MET - NCT01734785
1276.1 (bitherapy MET) ongoing empagliflozin + METMET - NCT01719003
1245.29 ongoing empagliflozinplacebo - NCT02182830
99050 ongoing empagliflozinplacebo (add on MET+/-SU) - NCT01257334
EASE-2 ongoing empagliflozinPlacebo (add-on INS) - NCT02414958
1275.19 ongoing empagliflozinplacebo add-on linagliptin - NCT02453555



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons